{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:52:23Z","timestamp":1783479143484,"version":"3.55.0"},"reference-count":0,"publisher":"Codon Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergol Immunopathol"],"abstract":"<jats:p>Background: Atopic dermatitis (AD) is common in children (affecting ~20% of children globally) and imposes a substantial burden. Many children in Latin America have moderate-to-severe AD with limited access to advanced therapies, highlighting an unmet need for safe and effective treatment options. Dupilumab, a targeted anti-interleukin-4 (IL-4)\u2013IL-13 biologic, has demonstrated efficacy in pediatric AD, but real-world data in Latin American children are scarce.\nMethods: We conducted a single-center retrospective observational study in Mexico City with children (aged 4\u201318 years) with moderate-to-severe AD treated with dupilumab from 2018 to 2024. Clinical outcomes (Eczema Area and Severity Index; Scoring Atopic Dermatitis [SCORAD], and pruritus Numerical Rating Scale [NRS]) and quality-of-life (Dermatology Life Quality Index) were assessed at baseline and ~3, ~6, and ~12 months. Changes over time were analyzed using nonparametric tests, and adverse events were documented.\nResults: In all, 23 children (~50% female) with severe, treatment-refractory AD were included. Dupilumab led to rapid and significant improvement in all endpoints (P &lt; 0.001). In 12 months, most patients achieved clear or almost clear skin with no pruritus (median SCORAD and itch NRS = 0), and quality-of-life scores improved from a median of 19 to 3. No serious adverse events occurred; mild conjunctivitis was reported in 13% patients (with one discontinuation).\nConclusion: In this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.<\/jats:p>","DOI":"10.15586\/aei.v54i2.1402","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:15:46Z","timestamp":1772464546000},"page":"28-34","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study"],"prefix":"10.15586","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-7108","authenticated-orcid":false,"given":"Victor","family":"Gonzalez-Uribe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Rodrigo","family":"Pastrana-Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Angel","family":"Hernandez-Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Andres","family":"Gomez-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Julia","family":"Rendon-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hernandez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Martinez-Tenopala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira Selene","family":"Mojica-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","published-online":{"date-parts":[[2026,3,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1402\/2284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1402\/2285","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1402\/2286","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1402\/2284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T10:25:20Z","timestamp":1773570320000},"score":1,"resource":{"primary":{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/view\/1402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v54i2.1402","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}